Q2 FY2026 Earnings
Financial report interval: 2025.10.01 - 2025.12.31
Overview: Regencell Bioscience(RGC) the EBIT is -2.67 M (-170%);the EPS is -0.0054 (-186.9%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
EBIT
-0.00B170.02%
----
----
EPS
-0.0054186.93%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf